Figure 4 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

VEGF and IL8 expression is altered and plays a role in resistance in enzalutamide-resistant prostate cancer cell lines. Cells were treated with anti-IL8 nAb (5 μg/mL), anti-VEGF nAb (10 μg/mL), or the highest concentration of isotype-matched human IgG antibody. A, qRT-PCR data comparing basal expression of VEGFA and CXCL8 (IL8) expression in LNCaP-Parental (PAR), LNCaP-EnzR, CWR-R1-Par, and CWR-R1-EnzR cell lines. B, ELISA data comparing basal secretion of VEGF and IL8 in LNCaP-Par, LNCaP-EnzR, CWR-R1-Par, and CWR-R1-EnzR cells. Data shown are the mean±SEM of N = 4 experiments. C–F, Bar graphs demonstrating the effect of combined treatment with anti-IL8 nAb and anti-VEGF nAb on the response of LNCaP-Par, LNCaP-EnzR, CWR-R1-Par, and CWR-R1-EnzR cells to 10 μmol/L Enz over 72 hours in (C and D) normoxia and (E and F) hypoxia. All experiments data represented as the mean ± SEM of N = 3 experiments, unless otherwise stated and statistical analysis was carried out using a Mann-Whitney U test: *, P < 0.05; **, P < 0.01.